KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Inventory: 2014-2024

Historic Inventory for Travere Therapeutics (TVTX) over the last 11 years, with Dec 2024 value amounting to $6.2 million.

  • Travere Therapeutics' Inventory fell 12.71% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 12.71%. This contributed to the annual value of $6.2 million for FY2024, which is 34.11% down from last year.
  • Latest data reveals that Travere Therapeutics reported Inventory of $6.2 million as of FY2024, which was down 34.11% from $9.4 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Inventory ranged from a high of $9.4 million in FY2023 and a low of $4.5 million during FY2022.
  • Over the past 3 years, Travere Therapeutics' median Inventory value was $6.2 million (recorded in 2024), while the average stood at $6.7 million.
  • As far as peak fluctuations go, Travere Therapeutics' Inventory slumped by 38.15% in 2022, and later spiked by 108.05% in 2023.
  • Over the past 5 years, Travere Therapeutics' Inventory (Yearly) stood at $7.6 million in 2020, then decreased by 3.88% to $7.3 million in 2021, then plummeted by 38.15% to $4.5 million in 2022, then spiked by 108.05% to $9.4 million in 2023, then crashed by 34.11% to $6.2 million in 2024.